You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNorethindrone
Accession NumberDB00717  (APRD00679)
TypeSmall Molecule
GroupsApproved
Description

A synthetic progestational hormone with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(17alpha)-17-Ethynyl-17-hydroxyestra-4,8(14),9-trien-3-oneNot AvailableNot Available
17-alpha-Ethynyl-17-hydroxy-4-estren-3-oneNot AvailableNot Available
17-alpha-Ethynyl-19-norandrost-4-en-17-beta-ol-3-oneNot AvailableNot Available
17-alpha-Ethynyl-19-nortestosteroneNot AvailableNot Available
17-alpha-Ethynyl-4-estren-17-ol-3-oneNot AvailableNot Available
17-beta-Hydroxy-19-norpregn-4-en-20-yn-3-oneNot AvailableNot Available
17-Hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-oneNot AvailableNot Available
17-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-oneNot AvailableNot Available
17alpha-Ethinyl-19-nortestosteroneNot AvailableNot Available
17alpha-Ethinylestra-4-en-17beta-ol-3-oneNot AvailableNot Available
17alpha-Ethynyl-17-hydroxy-4-estren-3-oneNot AvailableNot Available
17alpha-Ethynyl-17beta-hydroxy-19-norandrost-4-en-3-oneNot AvailableNot Available
17alpha-Ethynyl-19-nor-4-androsten-17beta-ol-3-oneNot AvailableNot Available
17alpha-Ethynyl-19-norandrost-4-en-17beta-ol-3-oneNot AvailableNot Available
17alpha-Ethynyl-19-nortestosteroneNot AvailableNot Available
17alpha-Ethynyl-4-estren-17-ol-3-oneNot AvailableNot Available
17beta-Hydroxy-19-norpregn-4-en-20-yn-3-oneNot AvailableNot Available
17α-ethinyl-19-nortestosteroneNot AvailableNot Available
19-Nor-17-alpha-ethynyl-17-beta-hydroxy-4-androsten-3-oneNot AvailableNot Available
19-Nor-17-alpha-ethynylandrosten-17-beta-ol-3-oneNot AvailableNot Available
19-Nor-17-alpha-ethynyltestosteroneNot AvailableNot Available
19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-oneNot AvailableNot Available
19-Nor-17alpha-ethynylandrosten-17beta-ol-3-oneNot AvailableNot Available
19-Nor-17alpha-ethynyltestosteroneNot AvailableNot Available
19-nor-17α-ethynyltestosteroneNot AvailableNot Available
19-Nor-ethindroneNot AvailableNot Available
19-NorethisteroneNot AvailableNot Available
4-Estren-17alpha-ethynyl-17beta-ol-3-oneNot AvailableNot Available
CamilaNot AvailableNot Available
ConludagNot AvailableNot Available
MicronorNot AvailableNot Available
MicronovumNot AvailableNot Available
Mini-PENot AvailableNot Available
Mini-pillNot AvailableNot Available
NorcolutNot AvailableNot Available
NorethindroneNot AvailableNot Available
NorethisteronNot AvailableNot Available
NorethisteroneNot AvailableINN
NorethisteronumLatinINN
NoretisteronaSpanishINN
NoridayNot AvailableNot Available
NorlutenNot AvailableNot Available
NorlutinNot AvailableNot Available
Primolut-NNot AvailableNot Available
UtovlanNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ortho Micronortablet.35 mgoralJanssen Pharmaceuticals, Inc.1973-01-02Not AvailableUs
Nor Qdtablet.35 mgoralWatson Pharma, Inc.1973-01-02Not AvailableUs
Nora Betablet.35 mgoralWatson Pharma, Inc.2005-05-12Not AvailableUs
Jolivettetablet.35 mgoralActavis Pharma, Inc.2003-03-01Not AvailableUs
Micronortablet.35 mgoralPhysicians Total Care, Inc.2003-09-17Not AvailableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norethindronetablet.35 mgoralMylan Pharmaceuticals Inc.2013-06-24Not AvailableUs
Norethindronetablet.35 mgoralMylan Pharmaceuticals Inc.2013-07-12Not AvailableUs
Norethindrone Acetatetablet5 mgoralBarr Laboratories Inc.2001-06-29Not AvailableUs
Errintablet.35 mgoralBarr Laboratories Inc.2003-01-08Not AvailableUs
Camilatablet.35 mgoralBarr Laboratories Inc.2002-10-30Not AvailableUs
NorethindronekitNorthstar Rx LLC2013-09-07Not AvailableUs
NorethindronekitNorthstar Rx LLC2013-09-10Not AvailableUs
DeblitanekitNorthstar Rx LLC2014-06-01Not AvailableUs
SharobelkitNorthstar Rx LLC2014-06-01Not AvailableUs
Norethindrone Acetatetablet5 mgoralAv Kare, Inc.2013-06-18Not AvailableUs
Lyzatablet.35 mgoralAfaxys Inc.2013-06-24Not AvailableUs
Norethindrone Acetatetablet5 mgoralAv Pak2014-11-17Not AvailableUs
Aygestintablet5 mgoralTeva Women's Health, Inc.2003-06-12Not AvailableUs
Norlyroctablet, film coated.35 mgoralOhm Laboratories Inc.2014-04-15Not AvailableUs
Camilatablet.35 mgoralPhysicians Total Care, Inc.2003-06-19Not AvailableUs
Norethindrone Acetatetablet5 mgoralAmneal Pharmaceuticals2009-07-01Not AvailableUs
Norethindronetablet.35 mgoralLupin Pharmaceuticals, Inc.2011-11-10Not AvailableUs
Jencyclatablet.35 mgoralLupin Pharmaceuticals, Inc.2013-05-08Not AvailableUs
Heathertablet.35 mgoralGlenmark Generics Inc2010-04-23Not AvailableUs
Norethindrone Acetatetablet5 mgoralGlenmark Generics Inc., USA2010-07-21Not AvailableUs
Norethindronetablet.35 mgoralGlenmark Generics Inc.,USA2010-11-03Not AvailableUs
Over the Counter ProductsNot Available
International Brands
NameCompany
Primolut-NNot Available
Brand mixtures
Brand NameIngredients
Brevicon 0.5/35 (21 day)Ethinyl Estradiol + Norethindrone
Brevicon 0.5/35 (28 day)Ethinyl Estradiol + Norethindrone
Brevicon 0.5/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Brevicon 0.5/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Brevicon 1/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Brevicon 1/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
CombiPatchNorethindrone + Estradiol
Estalis 140/50 McgEstradiol + Norethindrone Acetate
Estalis 250/50 McgEstradiol + Norethindrone Acetate
Estalis SequiEstradiol + Norethindrone Acetate
EstracombEstradiol + Norethindrone Acetate
femhrtNorethindrone + Ethinyl Estradiol
Femhrt 1/5Ethinyl Estradiol + Norethindrone Acetate
JINTELINorethindrone + Ethinyl Estradiol
Lo Minastrin Norethindrone acetate, ethinyl estradiol, ferrous fumarate
Loestrin 1.5/30 21-day PackEthinyl Estradiol + Norethindrone Acetate
Loestrin 1.5/30 28-day PackEthinyl Estradiol + Norethindrone Acetate
MimveyNorethindrone + Estradiol
Minestrin 1/20 21Ethinyl Estradiol + Norethindrone Acetate
Minestrin 1/20 28Ethinyl Estradiol + Norethindrone Acetate
Norinyl 1/50 - 21-day packMestranol + Norethindrone
Norinyl 1/50 - 28-day packMestranol + Norethindrone
Norinyl 1/50 (21 day)Mestranol + Norethindrone
Norinyl 1/50 (28 day)Mestranol + Norethindrone
Ortho 0.5/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 0.5/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho 1/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 1/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho 10/11 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 10/11 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho 7/7/7 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 7/7/7 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho-Novum 1/50 Tablets (21 day)Mestranol + Norethindrone
Ortho-Novum 1/50 Tablets (28 day)Mestranol + Norethindrone
Select 1/35 (21 day)Ethinyl Estradiol + Norethindrone
Select 1/35 (28 day)Ethinyl Estradiol + Norethindrone
Synphasic (21 day)Ethinyl Estradiol + Norethindrone
Synphasic (28 day)Ethinyl Estradiol + Norethindrone
Salts
Name/CASStructureProperties
Norethindrone Acetate
Thumb
  • InChI Key: IMONTRJLAWHYGT-ZCPXKWAGSA-N
  • Monoisotopic Mass: 340.203844762
  • Average Mass: 340.4559
DBSALT000129
Categories
CAS number68-22-4
WeightAverage: 298.4192
Monoisotopic: 298.193280076
Chemical FormulaC20H26O2
InChI KeyVIKNJXKGJWUCNN-XGXHKTLJSA-N
InChI
InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14R,15S)-14-ethynyl-14-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Ynone
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationNorethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
PharmacodynamicsNorethindrone is a synthetic oral progestin. It is used for contraception or to treat such conditions as secondary amenorrhea, abnormal uterine bleeding, and endometriosis. As an oral contraceptive, norethindrone is available as either a single agent or in combination with an estrogen. Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone.
Mechanism of actionProgestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
AbsorptionNorethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone is rapidly absorbed from norethindrone acetate, in which maximum plasma concentration occur 2 hours post-dose (Tmax). When a single dose is given to healthy women, the Cmax is 26.19 ± 6.19 hours. The AUC (0-inf) is 166.90 ± 56.28 ng/mL*h. Absolute oral bioavailability is approximately 64%. The effect of food on the pharmacokinetics of norethindrone acetate is unknown.
Volume of distribution
  • 4 L/kg
Protein bindingNorethindrone is 36% bound to sex hormone-binding globulin and 61% bound to albumin.
Metabolism

Hepatic. Norethindrone is extensively metabolized, primarily via reduction. It also undergoes sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.

Route of eliminationNorethindrone is excreted in both urine and feces, primarily as metabolites.
Half life8.51 ± 2.19 (when a single dose is given to healthy women)
Clearance
  • 0.4 L/hr/kg [plasma clearance]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9413
Caco-2 permeable+0.8572
P-glycoprotein substrateSubstrate0.6346
P-glycoprotein inhibitor IInhibitor0.5079
P-glycoprotein inhibitor IINon-inhibitor0.9087
Renal organic cation transporterNon-inhibitor0.7603
CYP450 2C9 substrateNon-substrate0.7759
CYP450 2D6 substrateNon-substrate0.9237
CYP450 3A4 substrateSubstrate0.7415
CYP450 1A2 substrateNon-inhibitor0.844
CYP450 2C9 substrateNon-inhibitor0.8688
CYP450 2D6 substrateNon-inhibitor0.9386
CYP450 2C19 substrateInhibitor0.8994
CYP450 3A4 substrateNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7876
Ames testNon AMES toxic0.9319
CarcinogenicityNon-carcinogens0.9417
BiodegradationNot ready biodegradable0.9512
Rat acute toxicity1.8788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8777
hERG inhibition (predictor II)Non-inhibitor0.7744
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
  • Barr laboratories inc
  • Glenmark generics ltd
  • Ortho mcneil janssen pharmaceuticals inc
  • Watson laboratories inc
  • Duramed research inc
  • Glenmark generics ltd india
  • Warner Chilcott
Packagers
Dosage forms
FormRouteStrength
Kit
Tabletoral.35 mg
Tabletoral5 mg
Tablet, film coatedoral.35 mg
Prices
Unit descriptionCostUnit
Ovcon-35 (28) 28 0.4-35 mg-mcg tablet Disp Pack89.09USD disp
Ovcon-50 28 50-1 mcg-mg tablet Disp Pack89.09USD disp
Loestrin 1.5/30 (21) 21 1.5-30 mg-mcg tablet Disp Pack79.32USD disp
Loestrin 1/20 (21) 21 1-20 mg-mcg tablet Disp Pack79.32USD disp
Loestrin Fe 1/20 28 1-20 mg-mcg tablet Disp Pack79.32USD disp
Loestrin Fe 1.5/30 28 1.5-30 mg-mcg tablet Disp Pack77.1USD disp
Loestrin 24 Fe 28 1-20 mg-mcg tablet Disp Pack75.15USD disp
Nor-QD 28 0.35 mg tablet Disp Pack65.87USD disp
Tri-Norinyl (28) 28 0.5/1/0.5-35 mg-mcg tablet Disp Pack62.63USD disp
Ortho-Novum 10/11 (28) 28 35 mcg tablet Disp Pack60.25USD disp
Modicon (28) 28 0.5-35 mg-mcg tablet Disp Pack59.99USD disp
Norinyl 1+35 (28) 28 1-35 mg-mcg tablet Disp Pack55.99USD disp
Ortho-Novum 1/35 (28) 28 1-35 mg-mcg tablet Disp Pack55.99USD disp
Brevicon (28) 28 0.5-35 mg-mcg tablet Disp Pack53.0USD disp
Norinyl 1+50 (28) 28 1-50 mg-mcg tablet 1 Disp Pack = 28 Pills52.99USD disp
Necon 10/11 (28) 28 35 mcg tablet Disp Pack35.99USD disp
Ortho-Novum 7/7/7 (28) 28 0.5/0.75/1-35 mg-mcg tablet Disp Pack33.99USD disp
Necon 0.5/35 (28) 28 0.5-35 mg-mcg tablet Disp Pack32.99USD disp
Necon 1/35 (28) 28 1-35 mg-mcg tablet Disp Pack31.99USD disp
Loestrin fe 1-20 tablet5.23USD tablet
Loestrin 21 1.5-30 tablet3.66USD tablet
Loestrin 21 1-20 tablet3.66USD tablet
Aygestin 5 mg tablet3.27USD tablet
Ovcon-35 28 tablet3.06USD tablet
Loestrin fe 1.5-30 tablet2.75USD tablet
Norethindrone Acetate 5 mg tablet2.75USD tablet
Norethindrone 5 mg tablet2.65USD tablet
Ovcon-50 28 tablet2.62USD tablet
Micronor tablet2.44USD tablet
Nor-q-d tablet2.24USD tablet
Necon 1-35-28 tablet2.11USD tablet
Modicon 28 tablet2.07USD tablet
Tri-norinyl 28 tablet2.01USD tablet
Ortho-novum 1-35-28 tablet1.9USD tablet
Brevicon 28 tablet1.8USD tablet
Norinyl 1+35-28 tablet1.73USD tablet
Norinyl 1+50-28 tablet1.73USD tablet
Demulen 1-50-21 tablet1.67USD tablet
Ortho-novum 7-7-7-21 tablet1.4USD tablet
Errin 0.35 mg tablet1.34USD tablet
Ortho-novum 7/7/7-28 tablet1.33USD tablet
Camila tablet1.32USD tablet
Jolivette tablet1.32USD tablet
Nora-be tablet1.32USD tablet
Norethindrone 0.35 mg tablet1.32USD tablet
Demulen 1-50-28 tablet1.29USD tablet
Ortho micronor tablet1.23USD tablet
Necon 0.5-35-28 tablet1.15USD tablet
Necon 7-7-7-28 tablet1.15USD tablet
Necon 1-50-28 tablet1.05USD tablet
Ortho-novum 7-7-7-28 tablet1.02USD tablet
Micronor (28 Day) 0.35 mg Tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point203.5 °CPhysProp
water solubility7.04 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.97HANSCH,C ET AL. (1995)
logS-4.57ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00668 mg/mLALOGPS
logP2.72ALOGPS
logP3.22ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)17.59ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity87.42 m3·mol-1ChemAxon
Polarizability34.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.3 KB)
SpectraMS1D NMR
References
Synthesis ReferenceNot Available
General Reference
  1. FDA label
External Links
ATC CodesG03AC01G03DC02
AHFS Codes
  • 68:12.00
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (73.9 KB)
Interactions
Drug Interactions
Drug
AcitretinAcitretine may cause a loss of contraceptive effect
AmobarbitalThis product may cause a slight decrease of contraceptive effect
AprobarbitalThis product may cause a slight decrease of contraceptive effect
ArtemetherArtemether may decrease the effectiveness of norethindrone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
BexaroteneBexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
BosentanBosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
ButabarbitalThis product may cause a slight decrease of contraceptive effect
ButalbitalThis product may cause a slight decrease of contraceptive effect
ButethalThis product may cause a slight decrease of contraceptive effect
CarbamazepineThis product may cause a slight decrease of contraceptive effect
ColesevelamBile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
EthotoinThis product may cause a slight decrease of contraceptive effect
FosphenytoinThis product may cause a slight decrease of contraceptive effect
GriseofulvinThis product may cause a slight decrease of contraceptive effect
HeptabarbitalThis product may cause a slight decrease of contraceptive effect
HexobarbitalThis product may cause a slight decrease of contraceptive effect
LamotrigineThe oral contraceptive decreases the effect of lamotrigine
MephenytoinThis product may cause a slight decrease of contraceptive effect
MethohexitalThis product may cause a slight decrease of contraceptive effect
MethylphenobarbitalThis product may cause a slight decrease of contraceptive effect
PentobarbitalThis product may cause a slight decrease of contraceptive effect
PhenobarbitalThis product may cause a slight decrease of contraceptive effect
PhenytoinThis product may cause a slight decrease of contraceptive effect
PioglitazonePossible loss of contraceptive effect
PrimidoneThis product may cause a slight decrease of contraceptive effect
RifabutinRifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
RifampicinThis product may cause a slight decrease of contraceptive effect
RifapentineThis product may cause a slight decrease of contraceptive effect
RufinamideRufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification
SecobarbitalThis product may cause a slight decrease of contraceptive effect
St. John's WortSt. John's Wort could reduce the contraceptive effect
TalbutalThis product may cause a slight decrease of contraceptive effect
ThiopentalThiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
TizanidineThe contraceptive increases the effect of tizanidine
TretinoinOral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy.
TroglitazonePossible loss of contraceptive effect
WarfarinNorethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed.
Food Interactions
  • Take without regard to meals.

Targets

1. Progesterone receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
Progesterone receptor P06401 Details

References:

  1. Mendoza-Rodriguez CA, Camacho-Arroyo I, Garcia GA, Cerbon MA: Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites. Contraception. 1999 May;59(5):339-43. Pubmed
  2. Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. Pubmed
  3. Garcia-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Perez-Palacios G, Larrea F: Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins. J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):21-7. Pubmed
  4. Mirkin S, Wong BC, Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 Aug;84(2):485-91. Pubmed
  5. Pasapera AM, Cerbon MA, Castro I, Gutierrez R, Camacho-Arroyo I, Garcia GA, Perez-Palacios G: Norethisterone metabolites modulate the uteroglobin and progesterone receptor gene expression in prepubertal rabbits. Biol Reprod. 1995 Feb;52(2):426-32. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. FDA label

2. Sex hormone-binding globulin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Sex hormone-binding globulin P04278 Details

References:

  1. FDA label

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11